Profile data is unavailable for this security.

About the company

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

  • Revenue in GBP (TTM)18.39bn
  • Net income in GBP1.70bn
  • Incorporated1992
  • Employees61.50k
  • Location
    AstraZeneca PLC- Legal Department, 2 Kingdom StreetLONDON W2 6BDUnited KingdomGBR
  • Phone+44 20 7304 5000Fax+44 20 7604 8151
  • Websitehttp://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
announced
Transaction
value
Takeda Pharmaceutical Co Ltd-Respiratory BusinessDeal completed16 Dec 201516 Dec 2015Deal completed13.08%575.00m
Acerta Pharma BVDeal completed14 Dec 201514 Dec 2015Deal completed14.68%4.00bn
ZS Pharma IncDeal completed06 Nov 201506 Nov 2015Deal completed16.92%2.69bn
Amgen Inc-Biologics Bulk Manufacturing FacilityDeal completed11 Sep 201511 Sep 2015Deal completed15.73%--
Data delayed at least 20 minutes, as of Aug 31 2016 08:38 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Shire PLC5.74bn960.63m43.68bn5.55k43.68bn5.55k
GlaxoSmithKline plc25.17bn31.00m80.17bn101.19k80.17bn101.19k
Sanofi SA34.12bn4.15bn89.83bn115.63k89.83bn115.63k
AstraZeneca plc18.39bn1.70bn133.04bn61.50k133.04bn61.50k
Novo Nordisk A/S110.34bn36.06bn635.97bn42.27k635.97bn42.27k
Data as of Aug 31 2016. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

22.56%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Jan 201653.17m4.21%
Wellington Management Co. LLPas of 01 Jun 201638.31m3.03%
Legal & General Investment Management Ltd.as of 01 Jun 201636.68m2.90%
The Vanguard Group, Inc.as of 01 Jun 201630.04m2.38%
BlackRock Advisors LLCas of 01 Jun 201623.18m1.83%
Invesco Asset Management Ltd.as of 01 Jun 201622.46m1.78%
Woodford Investment Management LLPas of 01 Jun 201622.32m1.77%
Norges Bank Investment Managementas of 01 Jun 201621.92m1.73%
Threadneedle Asset Management Ltd.as of 01 Jun 201619.41m1.54%
State Street Global Advisors Ltd.as of 01 Jun 201617.73m1.40%
More ▼
Data from 31 Dec 2015 - 24 Aug 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.